Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Discuss the cardinal features of inflammation and the primary role that inflammation and airway remodeling plays in the pathophysiology of asthma.
- Explain the link between inflammation and the severity of asthma.
- Appreciate the heterogeneity of airway pathophysiology.
- Describe the potential added benefits of more non-invasive measures of inflammation in assessing asthma control.
- Identify important therapeutic targets in the inflammation of airways.
Target Audience
This activity is intended for Family Practitioners, Physician Assistants, Registered Nurses, Nurse Practitioners, and other Allied Health professionals interested in the treatment of asthma.
Accreditation and Designation Statement
National Jewish Medical and Research Center is accredited by the ACCME to provide Continuing Medical Education for physicians. National Jewish designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participating Faculty
Rafeul Alam, MD, PhD
Veda & Chauncey Ritter Chair in Immunology
Professor & Director, Division of Allergy & Immunology
National Jewish Medical & Rsearch Center
University of Colorado Health Sciences Center
Denver, CO
Ronald Balkissoon, MD, MSc
Associate Professor
Department of Medicine
National Jewish Medical and Research Center
Denver, CO
David Beuther, MD
Associate Professor
Department of Medicine
National Jewish Medical and Research Center
University of Colorado Health Science Center,
Denver, CO
Leonard Fromer, MD, FAAFP
Assistant Clinical Professor
Department of Family Medicine
University of California, Los Angeles
Los Angeles, CA
Richard Martin, MD
Chairman, Department of Medicine
Edelstein Family Chair in Pulmonary Medicine
National Jewish Medical and Research Center
Professor of Medicine
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, CO
Harold Nelson, MD
Professor of Medicine
Department of Medicine
National Jewish Medical and Research Center
Professor of Medicine
University of Colorado School of Medicine
Denver, CO
Stanley J. Szefler, MD
Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics,
Head, Divisions of Pediatric Clinical Pharmacology,
Department of Pediatrics
National Jewish Medical and Research Center;
Professor of Pediatrics and Pharmacology
University of Colorado Health Science Center,
Denver, CO
Barbara P. Yawn, MD, MSc
Director of Research
Olmsted Medical Center
Adjunct Professor
Department of Family Medicine and Community Health
University of Minnesota
Rochester, MN
Faculty Disclosure
All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties. Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.
KEY
# Grant Support
~ Speaker’s Bureau
^ Consultant
> Other
Ron Balkissoon, MD
^ AstraZeneca
~ AstraZeneca, Boehringer-Ingelheim, Genentech, GSK, Novartis
David Beuther, MD
# Merck & Co., Inc.
Ronina Covar, MD
^ AstraZeneca, Merck & Co., Inc.
# AstraZeneca, Ross Products/Abbott Laboratories
Stephen K. Frankel, MD
Has no significant financial interest to report
Leonard Fromer, MD
Has no significant financial interest to report
Richard Martin, MD
^ # ~ Altana, GlaxoSmithKline, Teva
^ ~ AstraZeneca, Genentech, Merck, Novartis, sanofi aventis
^ KaloBios, EarlySense
Harold Nelson, MD
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Schering-Plough (Integrated Therapeutics Group)
~ AstraZeneca, GlaxoSmithKline
# Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Sepracor, Inc., Novartis, Schering-Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd., Wyeth
Stanley Szefler, MD
^ AstraZeneca, Genentech, GlaxoSmithKline, Merck, Inc., Novartis, sanofi-aventis
Richard W. Weber, MD
^ AstraZeneca, Genentech/Novartis
~ AstraZeneca, Genentech/Novartis, GlaxoSmithKline
# Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.
Commercial Support
This program is supported by an educational grant from Schering-Plough.
Privacy Statement
Your personal information is confidential and will not be sold to other sources. We will use evaluation and post-test information to compile outcomes on this program.
|
Streaming Media